Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical)

雷珠单抗生物类似药 (Chong Kun Dang Pharmaceutical)

Report date: 2026/03/17 20:00:15

Base Information

Drug NameRanibizumab biosimilar (Chong Kun Dang Pharmaceutical)

Drug Alias Name雷珠单抗生物仿制药 (Chong Kun Dang Pharmaceutical)CKD-701

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesChong Kun Dang Pharmaceutical Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesChong Kun Dang Pharmaceutical Corp

Active IndicationsN/A

Inactive IndicationsMacular Degeneration

Other Information

ATC CodeS01LA04